<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03637348</url>
  </required_header>
  <id_info>
    <org_study_id>2018-008</org_study_id>
    <nct_id>NCT03637348</nct_id>
  </id_info>
  <brief_title>Effect of TrueTear Corneal Surface Imaging</brief_title>
  <official_title>Effect of TrueTear Use on Anterior Corneal Surface Imaging Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Price Vision Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Price Vision Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the utility of TrueTear™ to improve anterior corneal surface imaging
      quality before cataract surgery, refractive lens exchange, or laser refractive surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corneal imaging will be repeated before and after TrueTear use during a single patient visit.
      Image quality measures will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Actual">July 8, 2019</completion_date>
  <primary_completion_date type="Actual">July 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surface asymmetry index (SAI) assessed with corneal topography</measure>
    <time_frame>Change from baseline SAI at 5-10 minutes after using the TrueTear device.</time_frame>
    <description>Surface asymmetry index (SAI) is an index that indicates an average value of the corneal power differences between the points spatially located at 180° from 128 equidistant meridians. A radially symmetrical surface has a value of zero, and this value increases as the degree of asymmetry is greater.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surface regularity index (SRI) assessed with corneal topography</measure>
    <time_frame>Change from baseline SRI at 5-10 minutes after using the TrueTear device.</time_frame>
    <description>Surface Regularity index (SRI) is a local descriptor of surface regularity in a central 4.5 mm diameter area of the cornea. It correlates well with the value of visual acuity (p = 0.80, P &lt;0.001), assuming the cornea is the only limiting factor for vision. A normal cornea presents SRI values below 0.56 (the SRI would be 0 in a perfectly regular cornea). SRI values increase with increasing irregularity of the corneal surface.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Cataract</condition>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>TrueTear</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Use of TrueTear device to stimulate tear production</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TrueTear</intervention_name>
    <description>Ues of TrueTear neurostimulator</description>
    <arm_group_label>TrueTear</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo routine imaging for cataract surgery, refractive lens exchange or
             laser refractive surgery

        Exclusion Criteria:

          -  A cardiac pacemaker, implanted or wearable defibrillator, or other implanted metallic
             or electronic device (e.g. cochlear implant) in the head or neck

          -  Chronic or frequent nosebleeds, a bleeding disorder (e.g. hemophilia), or another
             condition that can lead to increased bleeding

          -  A known hypersensitivity (allergy) to the hydrogel material that comes into contact
             with the inside of the nose during use of the TrueTearTM device

          -  Pregnancy

          -  Presence of any ocular disease or condition which in the investigator's opinion would
             confound the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 3, 2020</submitted>
    <returned>July 20, 2020</returned>
    <submitted>July 20, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

